Component
Circulating tumor necrosis factor alpha concentration
Circulating tumor necrosis factor alpha concentration. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
TNF-alpha decreased in the vitamin-D3, chromium and combined-treatment groups.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/chromium-research/31593637.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9", "start_char": 0, "end_char": 1523, "text_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9"}
- experimental_model
- Four-arm randomized supplementation trial; 92 participants
- exposure
- Four months; vitamin D3 50,000 IU/week, chromium picolinate reported as 500 µg/day, both or placebo
- limitations
- Study regimens are historical exposures, not recommendations. Stable versus rising HOMA-IR does not show direct mediation by TNF-alpha; no molecular target was tested.
- nutrient_topic
- Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium
- organism
- Human with type 2 diabetes
- plain_language
- The inflammatory marker changed in several active-treatment groups; this does not establish why HOMA-IR differed.
- primary_references
- [chromium-p31593637] The effects of chromium and vitamin D3 co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31593637/ DOI: 10.1139/apnm-2019-0113
- tissue_or_cell_type
- Blood glycemia, HOMA-IR and TNF-alpha
Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 666–677
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Four-arm randomized supplementation trial; 92 participants · source_derived_draft · unverified_draft
### chromium-vitd-tnf TNF-alpha decreased in the vitamin-D3, chromium and combined-treatment groups. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The inflammatory marker changed in several active-treatment groups; this does not establish why HOMA-IR differed. organism: Human with type 2 diabetes tissue_or_cell_type: Blood glycemia, HOMA-IR and TNF-alpha experimental_model: Four-arm randomized supplementation trial; 92 participants limitations: Study regimens are historical exposures, not recommendations. Stable versus rising HOMA-IR does not show direct mediation by TNF-alpha; no molecular target was tested. exposure: Four months; vitamin D3 50,000 IU/week, chromium picolinate reported as 500 µg/day, both or placebo evidence_span: {"source_cache": "artifacts/chromium-research/31593637.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9", "start_char": 0, "end_char": 1523, "text_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9"} [chromium-p31593637] The effects of chromium and vitamin D3 co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31593637/ DOI: 10.1139/apnm-2019-0113
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.